Literature DB >> 8266157

Topical nasal anaesthesia for fibreoptic bronchoscopy: lignocaine spray or gel?

B M Zainudin1, M H Rafia, A W Sufarlan.   

Abstract

Lignocaine spray for anaesthetising the nasal mucosa for fibreoptic bronchoscopy often causes discomfort to the patient. We compared two techniques of applying nasal topical anaesthesia using either lignocaine spray (group A: 25 patients) or gel (group B: 30 patients) to assess patients' tolerance to the procedure. Both groups received 100 mg of lignocaine in the nostril, 40-50 mg to oropharynx, 120 mg to vocal cords and 40-100 mg to trachea and bronchi. Throat anaesthesia was the most common unpleasant part experienced by both groups of patients (34.5%), followed by examination of bronchi (30.6%) and nasal anaesthesia (21.8%). Significantly more patients in group A experienced discomfort or pain during nasal anaesthesia as compared to group B (p < 0.001). Patients' tolerance to the bronchoscopy was similar in both groups and the examination was performed satisfactorily in all patients. Thus, lignocaine gel is a simple technique, effective and less irritating as compared to lignocaine spray for topical nasal anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8266157

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  3 in total

Review 1.  Complications and discomfort of bronchoscopy: a systematic review.

Authors:  Elise Orvedal Leiten; Einar Marius Hjellestad Martinsen; Per Sigvald Bakke; Tomas Mikal Lind Eagan; Rune Grønseth
Journal:  Eur Clin Respir J       Date:  2016-11-11

2.  A novel lidocaine hydrochloride ophthalmic gel for topical ocular anesthesia.

Authors:  Hr Shah; E Reichel; Bg Busbee
Journal:  Local Reg Anesth       Date:  2010-08-10

3.  Topical Nasal Anesthesia in Flexible Bronchoscopy--A Cross-Over Comparison between Two Devices.

Authors:  Thomas Fuehner; Jan Fuge; Meike Jungen; Anna Buck; Hendrik Suhling; Tobias Welte; Jens Gottlieb; Mark Greer
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.